|
Price: $8.3300
$-0.01 
-0.120%
|
| Day's High:
| $8.53
| Week Perf:
| 5.98 %
|
| Day's Low: |
$ 8.26 |
30 Day Perf: |
-6.19 % |
| Volume (M): |
37 |
52 Wk High: |
$ 13.77 |
| Volume (M$): |
$ 308 |
52 Wk Avg: |
$9.92 |
| Open: |
$8.43 |
52 Wk Low: |
$7.15 |
|
|
| Market Capitalization (Millions $) |
268 |
| Shares
Outstanding (Millions) |
32 |
| Employees |
500 |
| Revenues (TTM) (Millions $) |
194 |
| Net Income (TTM) (Millions $) |
6 |
| Cash Flow (TTM) (Millions $) |
-28 |
| Capital Exp. (TTM) (Millions $) |
1 |
Zynex Inc
Zynex Inc. is a medical device manufacturing company based in Lone Tree, Colorado, U.S.A. It was founded in 1996 by Thomas Sandgaard, who is currently the CEO and Chairman of the Board of Directors. Zynex specializes in the design, manufacture, and distribution of electrotherapy devices and other medical devices for pain management, rehabilitation, and neurological diagnostics.
The company has a broad range of products that cater to the needs of various patient populations. Its electrotherapy devices, which are its primary product line, are designed to relieve pain, treat muscle spasms, and promote tissue healing using electric currents. The electrotherapy devices include the NexWave, which is a non-invasive nerve stimulation system that provides pain relief, and the InWave, which is used for muscle rehabilitation and toning.
Zynex also manufactures and distributes the NeuroMove, a device that uses electrical stimulation to help people with paralysis and other neurological disorders improve their muscle function, and the Blood Volume Monitor, which is used by physicians to monitor blood volume during surgery and other medical procedures.
In addition to its product offerings, Zynex provides a range of services to healthcare providers, including training, support, and consulting services. The company has a team of experienced clinicians who assist healthcare providers in the selection, use, and maintenance of its medical devices.
Zynex has established itself as a leading player in the medical device industry, with its products being used by healthcare providers in the United States, Canada, and Mexico. The company has a strong commitment to research and development, and it invests heavily in clinical trials and other research initiatives to improve the quality and efficacy of its products.
Overall, Zynex Inc. is a highly reputable and innovative medical device manufacturing company that is committed to improving patient outcomes through the design and distribution of high-quality, safe, and effective medical devices.
Company Address: 9655 Maroon Cir Englewood 80112
Company Phone Number: 495-6670 Stock Exchange / Ticker: NASDAQ ZYXI
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Zynex Inc
In the second quarter of the 2024 earnings season, Zynex Inc, a Medical Equipment & Supplies company, experienced a reduction in earnings per share (EPS) despite an improvement in revenue. The income per share plummeted by -55.56% to $0.04 per share, while revenue increased by a respectable 10.969% to $49.88 million compared to the same quarter last year. However, the revenue surge of Zynex Inc is below the industry average of 14.88% relative to the Q2 of 2023.
Compared to the previous quarter, where EPS remained at $0.00 per share, and revenue advanced by 7.204% to $46.53 million, the current figures indicate a decline in the company's financial performance. The bottom-line of $1.217 million in the fiscal interval closing June 30, 2024, fell by -63.71% from $3.354 million in the corresponding period a year before.
Zynex Inc shifted its focus on improving sales during the fiscal interval closing June 30, 2024, resulting in a net margin of just 2.44%. This decrease in net margin can be attributed to the decline in operating earnings, which fell by -17.95% to $2.226 million. As a consequence, Zynex Inc's operating margin decreased to 4.46% from 6.04% in the second quarter of 2023.
|
| Zynex Inc
Zynex Inc Achieves Zero Gain per Share in Q1 of 2024, Future Performance Uncertain
In the fiscal first quarter of 2024, Zynex Inc (ZYXI) reported zero gain per share, a significant drop compared to $0.04 per share in the same period last year and the prior reporting period. This news might concern investors as they gauge the company's future performance and prospects.
However, there is a positive aspect to ZYXI's Q1 results. The company's revenue saw a 10.341% increase to $46.53 million from $42.17 million in the comparable reporting period a year ago. Although revenue decreased by -1.595% sequentially from $47.29 million, ZYXI's strong Q1 surge is in line with its peers in the Medical Equipment & Supplies sector, which collectively experienced a 9.75% increase in business during the first quarter of 2024.
|
| Zynex Inc
Zynex Inc, a medical equipment and supplies company, recently released its financial results for the fiscal period ending December 31, 2023. The figures show a significant decline in income, profit, and revenue compared to the previous year. While the wider Medical Equipment & Supplies sector witnessed revenue improvement, Zynex Inc struggled to maintain its performance. This article will delve into the financial details of Zynex Inc's results, outlining the facts and providing an interpretation of the company's current situation.
1. Declining Financial Performance:
For the fiscal period closing December 31, 2023, Zynex Inc reported an 80.6% decrease in income per share, amounting to $0.04 compared to $0.19 in the previous year. Moreover, profits plummeted by 63.8% from $0.10 per share in the preceding reporting period. This decline indicates a challenging period for the company, as it struggled to maintain profitability and generate investor returns.
|
| Zynex Inc
Zynex Inc Announces Financial Results for Q3 2023: Revenue Rises 20.2% but Net Income Drops 11.11%
Zynex Inc, a leading Medical Equipment & Supplies company, recently reported its financial results for the third quarter of 2023. Despite witnessing a remarkable 20.219% increase in revenue during the period, the company experienced a decline in net income per share, falling from $0.13 to $0.10. This decrease in net income can be attributed to the company's intensified focus on improving sales during the quarter.
Although the net profit per share showed growth of 11.11% from $0.09 to $0.10, it was unable to match the previous year's Q3 earnings. The financials revealed that Zynex Inc generated $44.95 million in revenue, which presents an 11.041% increase from the same period a year ago. However, the net income of $3.594 million in the third quarter of 2023 represented a significant decline of 26.25% compared to the $4.873 million the company earned in the corresponding period in 2022.
|
| Zynex Inc
Zynex Inc, a company operating in the Medical Equipment & Supplies sector, has demonstrated impressive growth and resilience in the second quarter of 2023. Despite the challenging conditions faced by many companies in the industry, Zynex Inc managed to significantly increase its earnings per share (EPS) and revenue.
In the second quarter of 2023, Zynex Inc reported an EPS of $0.09 per share, representing a 12.5% growth compared to $0.08 per share in the previous year. Furthermore, the company's earnings per share grew rapidly by 125% from $0.04 per share in the prior financial reporting period. This significant increase in EPS reflects the company's strong financial performance and ability to generate profits.
|
| Per Share |
Current |
| Earnings (TTM) |
0.18 $ |
| Revenues (TTM) |
6.01 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.96 $
|
| Book Value |
1.02 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0.18 $
|
| Revenues (TTM) |
6.01 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.96 $
|
| Book Value |
1.02 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
2.15%